title: Interstitial pneumonitis and lung fibrosis during adjuvant treatment of melanoma with interferon alpha according to the Kirkwood schedule.
authors.forename: J
authors.initials: J
authors.lastname: Puente Vázquez
authors.forename: F
authors.initials: F
authors.lastname: Moreno Antón
authors.forename: E
authors.initials: E
authors.lastname: Grande Pulido
authors.forename: S
authors.initials: S
authors.lastname: López Tarruella-Cobo
authors.forename: P
authors.initials: P
authors.lastname: Pérez Segura
authors.forename: E
authors.initials: E
authors.lastname: Díaz-Rubio
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003924:Diabetes Mellitus, Type 2; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D017563:Lung Diseases, Interstitial / Q000139:chemically induced / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000473:pathology; D008545:Melanoma / Q000188:drug therapy*; D010300:Parkinson Disease; D011658:Pulmonary Fibrosis / Q000139:chemically induced / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000473:pathology; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000188:drug therapy*; D014057:Tomography, X-Ray Computed; D014397:Tuberculosis, Pulmonary
chemical_list: D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins